TY - JOUR
T1 - Intraoperative molecular imaging
T2 - 3rd biennial clinical trials update
AU - Bou-Samra, Patrick
AU - Muhammad, Najib
AU - Chang, Austin
AU - Karsalia, Ritesh
AU - Azari, Feredun
AU - Kennedy, Gregory
AU - Stummer, Walter
AU - Tanyi, Janos
AU - Martin, Linda
AU - Vahrmeijer, Alexander
AU - Smith, Barbara
AU - Rosenthal, Eben
AU - Wagner, Patrick
AU - Rice, David
AU - Lee, Amy
AU - Abdelhafeez, Abdelhafeez
AU - Malek, Marcus M.
AU - Kohanbash, Gary
AU - Barry Edwards, Wilson
AU - Henderson, Eric
AU - Skjøth-Rasmussen, Jane
AU - Orosco, Ryan
AU - Gibbs, Summer
AU - Farnam, Richard W.
AU - Shankar, Lalitha
AU - Sumer, Baran
AU - Kumar, Anand T.N.
AU - Marcu, Laura
AU - Li, Lei
AU - Greuv, Victor
AU - Delikatny, Edward J.
AU - Lee, John Y.K.
AU - Singhal, Sunil
N1 - Publisher Copyright:
© The Authors. Published by SPIE under a Creative Commons Attribution 4.0 International License.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Significance: This third biennial intraoperative molecular imaging (IMI) conference shows how optical contrast agents have been applied to develop clinically significant endpoints that improve precision cancer surgery. Aim: National and international experts on IMI presented ongoing clinical trials in cancer surgery and preclinical work. Previously known dyes (with broader applications), new dyes, novel nonfluorescence-based imaging techniques, pediatric dyes, and normal tissue dyes were discussed. Approach: Principal investigators presenting at the Perelman School of Medicine Abramson Cancer Center's third clinical trials update on IMI were selected to discuss their clinical trials and endpoints. Results: Dyes that are FDA-approved or currently under clinical investigation in phase 1, 2, and 3 trials were discussed. Sections on how to move benchwork research to the bedside were also included. There was also a dedicated section for pediatric dyes and nonfluorescence-based dyes that have been newly developed. Conclusions: IMI is a valuable adjunct in precision cancer surgery and has broad applications in multiple subspecialties. It has been reliably used to alter the surgical course of patients and in clinical decision making. There remain gaps in the utilization of IMI in certain subspecialties and potential for developing newer and improved dyes and imaging techniques.
AB - Significance: This third biennial intraoperative molecular imaging (IMI) conference shows how optical contrast agents have been applied to develop clinically significant endpoints that improve precision cancer surgery. Aim: National and international experts on IMI presented ongoing clinical trials in cancer surgery and preclinical work. Previously known dyes (with broader applications), new dyes, novel nonfluorescence-based imaging techniques, pediatric dyes, and normal tissue dyes were discussed. Approach: Principal investigators presenting at the Perelman School of Medicine Abramson Cancer Center's third clinical trials update on IMI were selected to discuss their clinical trials and endpoints. Results: Dyes that are FDA-approved or currently under clinical investigation in phase 1, 2, and 3 trials were discussed. Sections on how to move benchwork research to the bedside were also included. There was also a dedicated section for pediatric dyes and nonfluorescence-based dyes that have been newly developed. Conclusions: IMI is a valuable adjunct in precision cancer surgery and has broad applications in multiple subspecialties. It has been reliably used to alter the surgical course of patients and in clinical decision making. There remain gaps in the utilization of IMI in certain subspecialties and potential for developing newer and improved dyes and imaging techniques.
KW - clinically significant events
KW - contrast agents
KW - intraoperative molecular imaging
KW - precision surgery
UR - http://www.scopus.com/inward/record.url?scp=85159482287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159482287&partnerID=8YFLogxK
U2 - 10.1117/1.JBO.28.5.050901
DO - 10.1117/1.JBO.28.5.050901
M3 - Review article
C2 - 37193364
AN - SCOPUS:85159482287
SN - 1083-3668
VL - 28
JO - Journal of biomedical optics
JF - Journal of biomedical optics
IS - 5
M1 - 050901
ER -